Skip to main content
Erschienen in: Die Innere Medizin 7/2008

01.07.2008 | Schwerpunkt

Antikoagulation und Gerinnungsstörungen in der Schwangerschaft

verfasst von: Dr. C. Gohlke-Bärwolf, S. Pildner von Steinburg, H. Kaemmerer, V. Regitz-Zagrosek

Erschienen in: Die Innere Medizin | Ausgabe 7/2008

Einloggen, um Zugang zu erhalten

Zusammenfassung

In der vorliegenden Übersicht sind die in der Schwangerschaft bedeutungsvollen Gerinnungsstörungen und die Behandlung mit Antikoagulanzien bei Patientinnen mit Herzklappenprothesen, Vorhofflimmern und Zustand nach thrombotischen Ereignissen zusammenfassend dargestellt. So benötigen Patientinnen mit mechanischen Klappenprothesen eine lebenslange orale Antikoagulation mit Coumarin(derivaten). Zur Therapie und Prävention von Thromboembolien sind unterschiedliche Behandlungsstrategien etabliert. Die Vor- und Nachteile verschiedener Therapieschemata der Antikoagulation während Schwangerschaft, Geburt und Stillzeit werden diskutiert und Empfehlungen für ein Management ausgesprochen, wobei jeweils auf die Risiken für Mutter und Feten eingegangen wird.
Literatur
1.
Zurück zum Zitat Arbeitsgemeinschaft Immunologie in Gynäkologie und Geburtshilfe der DGGG und DGGEF (2007) Stellungnahme zur Diagnostik und Therapie des wiederholten Spontanabortes (WSA) AWMF 015/050. http://www.dggg.de Arbeitsgemeinschaft Immunologie in Gynäkologie und Geburtshilfe der DGGG und DGGEF (2007) Stellungnahme zur Diagnostik und Therapie des wiederholten Spontanabortes (WSA) AWMF 015/050. http://​www.​dggg.​de
2.
Zurück zum Zitat Barbour LA, Kick SD, Steiner JF et al. (1994) A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 170: 862–869PubMed Barbour LA, Kick SD, Steiner JF et al. (1994) A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 170: 862–869PubMed
3.
Zurück zum Zitat Barbour LA, Oja JL, Schultz LK et al. (2004) A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 191: 1024–1029PubMedCrossRef Barbour LA, Oja JL, Schultz LK et al. (2004) A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 191: 1024–1029PubMedCrossRef
4.
Zurück zum Zitat Bauersachs RM, Dudenhausen J, Faridi A, Fischer T et al.; EThIG Investigators.(2007) Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 98: 1237–1245PubMed Bauersachs RM, Dudenhausen J, Faridi A, Fischer T et al.; EThIG Investigators.(2007) Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 98: 1237–1245PubMed
5.
Zurück zum Zitat Bonnar J (1994) Haemostasis and coagulation disorders in pregnancy. In: Bloom AL, Thomas DP (eds) Haemostasis and thrombosis. Churchill Livingstone, London, pp 570–583 Bonnar J (1994) Haemostasis and coagulation disorders in pregnancy. In: Bloom AL, Thomas DP (eds) Haemostasis and thrombosis. Churchill Livingstone, London, pp 570–583
6.
Zurück zum Zitat Bonow RO, Carabello BA, Chatterjee K et al. (2006) ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 48: e1–e148PubMedCrossRef Bonow RO, Carabello BA, Chatterjee K et al. (2006) ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 48: e1–e148PubMedCrossRef
7.
Zurück zum Zitat Butchart EG, Gohlke-Bärwolf C, Antunes MJ et al.; Working Groups on Valvular Heart Disease, Thrombosis and Cardiac Rehabilitation and Exercise Physiology, European Society of Cardiology (2005) Recommendations for the management of patients after heart valve surgery. Eur Heart J 26: 2463–2471PubMedCrossRef Butchart EG, Gohlke-Bärwolf C, Antunes MJ et al.; Working Groups on Valvular Heart Disease, Thrombosis and Cardiac Rehabilitation and Exercise Physiology, European Society of Cardiology (2005) Recommendations for the management of patients after heart valve surgery. Eur Heart J 26: 2463–2471PubMedCrossRef
8.
Zurück zum Zitat Chan WS, Anand S, Ginsberg JS (2000) Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 160: 191–196PubMedCrossRef Chan WS, Anand S, Ginsberg JS (2000) Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 160: 191–196PubMedCrossRef
9.
Zurück zum Zitat Clark SL, Porter TF, West FG (2000) Coumadin derivatives and breast feeding. Obstet Gynecol 95: 938–940PubMedCrossRef Clark SL, Porter TF, West FG (2000) Coumadin derivatives and breast feeding. Obstet Gynecol 95: 938–940PubMedCrossRef
10.
Zurück zum Zitat Cotrufo M, De Feo M, De Santo L et al. (2002) Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 99: 35–40PubMedCrossRef Cotrufo M, De Feo M, De Santo L et al. (2002) Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 99: 35–40PubMedCrossRef
11.
Zurück zum Zitat Daniel WG, Baumgartner H, Gohlke-Bärwolf C et al. (2006) Leitlinien Klappenvitien im Erwachsenenalter. Clin Res Cardiol 95: 620–641PubMedCrossRef Daniel WG, Baumgartner H, Gohlke-Bärwolf C et al. (2006) Leitlinien Klappenvitien im Erwachsenenalter. Clin Res Cardiol 95: 620–641PubMedCrossRef
12.
Zurück zum Zitat Dolovich LR, Ginsberg JS, Douketis JD et al. (2000) A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 160: 181–188PubMedCrossRef Dolovich LR, Ginsberg JS, Douketis JD et al. (2000) A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 160: 181–188PubMedCrossRef
13.
Zurück zum Zitat Duhl AJ, Paidas MJ, Ural SH et al. (2007) Antithrombotic therapy and pregnancy. Consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 197: 457.e1–21PubMedCrossRef Duhl AJ, Paidas MJ, Ural SH et al. (2007) Antithrombotic therapy and pregnancy. Consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 197: 457.e1–21PubMedCrossRef
14.
Zurück zum Zitat Elkayam U, Bitar F (2005) Valvular heart disease and pregnancy: part II: prosthetic valves. J Am Coll Cardiol 46: 403–410PubMedCrossRef Elkayam U, Bitar F (2005) Valvular heart disease and pregnancy: part II: prosthetic valves. J Am Coll Cardiol 46: 403–410PubMedCrossRef
15.
Zurück zum Zitat Elkayam U, Singh H, Irani A, Akhter MW (2007) Anticoagulation in pregnant women with prosthetic heart valves. J Cardiovasc Pharmacol Ther 9: 107–115CrossRef Elkayam U, Singh H, Irani A, Akhter MW (2007) Anticoagulation in pregnant women with prosthetic heart valves. J Cardiovasc Pharmacol Ther 9: 107–115CrossRef
16.
Zurück zum Zitat Empson M, Lassere M, Craig JC, Scott JR (2007) Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 99: 135–144CrossRef Empson M, Lassere M, Craig JC, Scott JR (2007) Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 99: 135–144CrossRef
17.
Zurück zum Zitat Ensom MH, Stephenson MD (1999) Low-molecular-weight heparins in pregnancy. Pharmacotherapy 19: 1013–1025PubMedCrossRef Ensom MH, Stephenson MD (1999) Low-molecular-weight heparins in pregnancy. Pharmacotherapy 19: 1013–1025PubMedCrossRef
18.
Zurück zum Zitat Fuster V, Ryden LE et al. (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: e257–e354PubMedCrossRef Fuster V, Ryden LE et al. (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: e257–e354PubMedCrossRef
19.
Zurück zum Zitat Gohlke-Bärwolf C (2001) Anticoagulation in pregnancy and post partum in heart valve diseases, thrombosis or atrial fibrillation: fetal risk versus maternal thromboembolism. Z Kardiol (Suppl 4) 90: 49–56 Gohlke-Bärwolf C (2001) Anticoagulation in pregnancy and post partum in heart valve diseases, thrombosis or atrial fibrillation: fetal risk versus maternal thromboembolism. Z Kardiol (Suppl 4) 90: 49–56
20.
Zurück zum Zitat Gohlke-Bärwolf C, Acar J, Oakley C et al. (1995) Recommendations for prevention of thromboembolism in heart valve diseases. Working Group on Valvular Heart Disease, European Society of Cardiology. Z Kardiol 84: 1018–1032PubMed Gohlke-Bärwolf C, Acar J, Oakley C et al. (1995) Recommendations for prevention of thromboembolism in heart valve diseases. Working Group on Valvular Heart Disease, European Society of Cardiology. Z Kardiol 84: 1018–1032PubMed
21.
Zurück zum Zitat Gris JC, Mercier E, Quéré I et al. (2004) Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 103: 3695–3699PubMedCrossRef Gris JC, Mercier E, Quéré I et al. (2004) Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 103: 3695–3699PubMedCrossRef
22.
Zurück zum Zitat Hall JG, Pauli RM, Wilson KM (1980) Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 68: 122–140PubMedCrossRef Hall JG, Pauli RM, Wilson KM (1980) Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 68: 122–140PubMedCrossRef
23.
Zurück zum Zitat Hanania G, Thomas D, Michel PL et al. (1994) Pregnancy and prosthetic heart valves: a French cooperative retrospective study of 155 cases. Eur Heart J 15: 1651–1658PubMed Hanania G, Thomas D, Michel PL et al. (1994) Pregnancy and prosthetic heart valves: a French cooperative retrospective study of 155 cases. Eur Heart J 15: 1651–1658PubMed
24.
Zurück zum Zitat Heit JA, Kobbervig CE, James AH et al. (2005) Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 143: 687–706 Heit JA, Kobbervig CE, James AH et al. (2005) Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 143: 687–706
25.
Zurück zum Zitat Kaemmerer H, Bauer U, Stein JI et al. (2003) Pregnancy in congenital cardiac disease: an increasing challenge for cardiologists and obstetricians – a prospective multicenter study. Z Kardiol 92: 16–23PubMedCrossRef Kaemmerer H, Bauer U, Stein JI et al. (2003) Pregnancy in congenital cardiac disease: an increasing challenge for cardiologists and obstetricians – a prospective multicenter study. Z Kardiol 92: 16–23PubMedCrossRef
26.
Zurück zum Zitat Kist JW, Janssen NG, Kalk JJ et al. (2008) Thrombophilias and adverse pregnancy outcome – A confounded problem! Thromb Haemost 99: 77–85PubMed Kist JW, Janssen NG, Kalk JJ et al. (2008) Thrombophilias and adverse pregnancy outcome – A confounded problem! Thromb Haemost 99: 77–85PubMed
27.
Zurück zum Zitat Lindqvist P, Dahlback B, Marsal K (1999) Thrombotic risk during pregnancy: a population study. Obstet Gynecol 94: 595–599PubMedCrossRef Lindqvist P, Dahlback B, Marsal K (1999) Thrombotic risk during pregnancy: a population study. Obstet Gynecol 94: 595–599PubMedCrossRef
28.
Zurück zum Zitat Marelli AJ, Mackie AS, Ionescu-Ittu R et al. (2007) Congenital heart disease in the general population. Circulation 115: 163–172PubMedCrossRef Marelli AJ, Mackie AS, Ionescu-Ittu R et al. (2007) Congenital heart disease in the general population. Circulation 115: 163–172PubMedCrossRef
29.
Zurück zum Zitat McKenna R, Cole ER, Vasan U (1983) Is warfarin sodium contraindicated in the lactating mother? J Pediatr 103: 325–327PubMedCrossRef McKenna R, Cole ER, Vasan U (1983) Is warfarin sodium contraindicated in the lactating mother? J Pediatr 103: 325–327PubMedCrossRef
30.
31.
Zurück zum Zitat O’Donnel MJ, Kearon C, Johnson J et al (2007) Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 146: 184–187 O’Donnel MJ, Kearon C, Johnson J et al (2007) Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 146: 184–187
32.
Zurück zum Zitat Ogasawara MS, Iinuma Y, Aoki K et al. (2001) Low-dose aspirin is effective for treatment of recurrent miscarriage in patients with decreased coagulation factor XII. Fertil Steril 76: 203–204PubMedCrossRef Ogasawara MS, Iinuma Y, Aoki K et al. (2001) Low-dose aspirin is effective for treatment of recurrent miscarriage in patients with decreased coagulation factor XII. Fertil Steril 76: 203–204PubMedCrossRef
33.
Zurück zum Zitat Oran B, Lee-Parritz A, Ansell J (2004) Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost 92: 747–751PubMed Oran B, Lee-Parritz A, Ansell J (2004) Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost 92: 747–751PubMed
34.
Zurück zum Zitat Poland BJ, Miller JR, Harris M, Livingston J (1981) Spontaneous abortion: a study of 1961 women and their conceptuses. Acta Obstet Gynecol Scand (Suppl) 102: 5–32 Poland BJ, Miller JR, Harris M, Livingston J (1981) Spontaneous abortion: a study of 1961 women and their conceptuses. Acta Obstet Gynecol Scand (Suppl) 102: 5–32
35.
Zurück zum Zitat Rai R, Cohen H, Dave M, Regan L (1997) Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies. BMJ 314: 253–257PubMed Rai R, Cohen H, Dave M, Regan L (1997) Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies. BMJ 314: 253–257PubMed
36.
Zurück zum Zitat Regitz-Zagrosek V, Gohlke-Bärwolf C, Geibel-Zehender AH et al. (2008) Leitlinie Herzerkrankungen in der Schwangerschaft, Positionspapier der DGK (in Druck) Regitz-Zagrosek V, Gohlke-Bärwolf C, Geibel-Zehender AH et al. (2008) Leitlinie Herzerkrankungen in der Schwangerschaft, Positionspapier der DGK (in Druck)
37.
Zurück zum Zitat Robertson L, Wu O, Langhorne P et al. (2006) Thrombophilia in pregnancy: a systematic review. Br J Haematol 132: 171–196PubMedCrossRef Robertson L, Wu O, Langhorne P et al. (2006) Thrombophilia in pregnancy: a systematic review. Br J Haematol 132: 171–196PubMedCrossRef
38.
Zurück zum Zitat Sbarouni E, Oakley CM (1994) Outcome of pregnancy in women with valve prostheses. Br Heart J 71: 196–201PubMedCrossRef Sbarouni E, Oakley CM (1994) Outcome of pregnancy in women with valve prostheses. Br Heart J 71: 196–201PubMedCrossRef
39.
Zurück zum Zitat Schaefer C, Hannemann D, Meister R et al. (2006) Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost 95: 949–957PubMed Schaefer C, Hannemann D, Meister R et al. (2006) Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost 95: 949–957PubMed
40.
Zurück zum Zitat Schaefer C, Spielmann H, Vetter K (2006) Arzneiverordnung in Schwangerschaft und Stillzeit, 7. Aufl. Urban & Fischer, München Jena Schaefer C, Spielmann H, Vetter K (2006) Arzneiverordnung in Schwangerschaft und Stillzeit, 7. Aufl. Urban & Fischer, München Jena
41.
Zurück zum Zitat Sotiriadis A, Makrigiannakis A, Stefos T et al. (2007) Fibrinolytic defects and recurrent miscarriage: a systematic review and meta-analysis. Obstet Gynecol 109: 1146–1155PubMed Sotiriadis A, Makrigiannakis A, Stefos T et al. (2007) Fibrinolytic defects and recurrent miscarriage: a systematic review and meta-analysis. Obstet Gynecol 109: 1146–1155PubMed
42.
Zurück zum Zitat Stephenson MD, PJ Ballem, Tsang P et al. (2004) Treatment of antiphospholipid antibody syndrome(APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynecol Canad 26: 729–734 Stephenson MD, PJ Ballem, Tsang P et al. (2004) Treatment of antiphospholipid antibody syndrome(APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynecol Canad 26: 729–734
43.
Zurück zum Zitat Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology (2003) Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 24: 761–781CrossRef Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology (2003) Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 24: 761–781CrossRef
44.
Zurück zum Zitat Vahanian A, Baumgartner H, Bax J et al. (2007) Guidelines on the management of valvular heart disease. Eur Heart J 28: 230–268PubMed Vahanian A, Baumgartner H, Bax J et al. (2007) Guidelines on the management of valvular heart disease. Eur Heart J 28: 230–268PubMed
45.
Zurück zum Zitat Vitale N, De Feo M, De Santo LS et al. (1999) Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 33: 1637–1641PubMedCrossRef Vitale N, De Feo M, De Santo LS et al. (1999) Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 33: 1637–1641PubMedCrossRef
Metadaten
Titel
Antikoagulation und Gerinnungsstörungen in der Schwangerschaft
verfasst von
Dr. C. Gohlke-Bärwolf
S. Pildner von Steinburg
H. Kaemmerer
V. Regitz-Zagrosek
Publikationsdatum
01.07.2008
Verlag
Springer-Verlag
Erschienen in
Die Innere Medizin / Ausgabe 7/2008
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI
https://doi.org/10.1007/s00108-008-2071-6

Weitere Artikel der Ausgabe 7/2008

Die Innere Medizin 7/2008 Zur Ausgabe

Mitteilungen der DGIM

Mitteilungen der DGIM 07/2008

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.